Advertisement

Cardiovascular Drugs and Therapy

, Volume 32, Issue 2, pp 181–181 | Cite as

Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials

  • Harold E. Bays
  • Robert S. Rosenson
  • Marie T. Baccara-Dinet
  • Michael J. Louie
  • Desmond Thompson
  • G. Kees Hovingh
Correction
  • 289 Downloads

Correction to: Cardiovasc Drugs Ther

https://doi.org/10.1007/s10557-018-6784-z

The original version of this article unfortunately contained a mistake in the Discussion section. The line that currently reads "During this 4-week period while off PCSK9 monoclonal antibody therapy, the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/or other lipid-altering drugs." should be changed to "During this 4-week stabilization period (while off PCSK9 monoclonal antibody therapy for at least 8 weeks), the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/or other lipid-altering drugs."

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Harold E. Bays
    • 1
  • Robert S. Rosenson
    • 2
  • Marie T. Baccara-Dinet
    • 3
  • Michael J. Louie
    • 4
  • Desmond Thompson
    • 4
  • G. Kees Hovingh
    • 5
  1. 1.Departments of Epidemiology & MedicineLouisville Metabolic and Atherosclerosis Research Center (L-MARC)LouisvilleUSA
  2. 2.Cardiometabolics Unit, Mount Sinai HeartIcahn School of Medicine at Mount SinaiNew YorkUSA
  3. 3.Clinical Development, R&DMontpellierFrance
  4. 4.Regeneron Pharmaceuticals, Inc.TarrytownUSA
  5. 5.Department of Vascular Medicine - Internal Medicine Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands

Personalised recommendations